药物发现和开发商Arctic Therapeutics完成超额认购的2150万美元融资-动脉网

Arctic Therapeutics closes oversubscribed US$21.5 million financing

CISION 等信源发布 2026-10-21 16:25



可切换为仅中文







The financing round, led by investment firm Pekron, Investcorp-backed Sanos Group, Icelandic investment company Kaldbakur and Landvættir, an Icelandic venture capital fund managed by AxUM Securities,

本轮融资由投资公司Pekron、获Investcorp支持的Sanos集团、冰岛投资公司Kaldbakur以及由AxUM Securities管理的冰岛风险投资基金Landvættir领投，

was

是

increased to US$21.5 million following strong investor demand

因投资者需求强劲，增至2150万美元

The proceeds will advance AT-002 and AT-003 towards clinical development

所得款项将推动AT-002和AT-003向临床开发阶段迈进

，

broadening the company's pipeline and building on key Phase II milestones achieved by its lead programs, AT-001 in rare and common forms of dementia and AT-004 in inflammatory skin diseases.

通过扩大公司产品管线，并依托其核心项目所取得的关键II期临床里程碑成果——即针对罕见及常见痴呆症的AT-001和针对炎症性皮肤病的AT-004。

The funding round follows the company's participation in the acquisition of the lead clinical-stage asset of US-based Nobias Therapeutics and the subsequent launch of Synaptiq Therapeutics

本轮融资紧随公司参与收购美国Nobias Therapeutics公司的领先临床阶段资产，并随后成立Synaptiq Therapeutics之后。

REYKJAVIK, Iceland AND PHILADELPHIA

冰岛雷克雅未克和费城

，

October 21, 2026

2026年10月21日

/PRNewswire/ -- Arctic Therapeutics (ATx), a clinical-stage biopharmaceutical company translating genetic discoveries into new treatments for diseases with significant unmet medical need, today announced the closing of an oversubscribed US$21.5 million financing round, which was increased following strong investor demand..

/美通社/ -- 临床阶段生物制药公司Arctic Therapeutics (ATx) 致力于将基因发现转化为针对存在重大未满足医疗需求疾病的新疗法，该公司今日宣布完成一轮超额认购的2,150万美元融资，该轮融资规模因投资者需求强劲而扩大。

The financing round was led by investment firm Pekron, Investcorp-backed Sanos Group, Icelandic investment company Kaldbakur and Landvættir, an Icelandic venture capital fund managed by AxUM Securities.

本轮融资由投资公司Pekron、获Investcorp支持的Sanos集团、冰岛投资公司Kaldbakur以及由AxUM Securities管理的冰岛风险投资基金Landvættir领投。

The proceeds will primarily be used to advance ATx's pipeline assets, AT-002 and AT-003, towards clinical development, expanding the company's clinical pipeline beyond its lead programs, AT-001 and AT-004, in rare and common forms of dementia and inflammatory skin diseases, respectively.

所得款项将主要用于推进ATx的管线资产AT-002和AT-003向临床开发阶段迈进，从而将公司的临床管线扩展至其领先项目AT-001（针对罕见型痴呆症）和AT-004（针对常见型炎症性皮肤病）之外。

The new financing follows the company's oversubscribed approximately US$31 million Series A round, which was allocated towards advancing the company's lead assets, AT-001 and AT-004. ATx has since achieved the clinical development milestones targeted with the Series A financing, with both programs reaching key Phase II clinical milestones..

此次新融资紧随公司超额认购的约3,100万美元A轮融资之后，该轮资金主要用于推进公司的核心资产AT-001和AT-004的研发。自那以来，Atx已实现了A轮融资所设定的临床开发里程碑，两个项目均达到了关键的II期临床里程碑。

'The support from both new and existing investors allows us to build on the substantial progress made across Arctic Therapeutics over the past two years,'

“新老投资者的支持使我们能够在过去两年中北极疗法公司取得的重大进展基础上继续前行。”

said Ivar Hakonarson, co-founder and chief executive officer.

联合创始人兼首席执行官伊瓦尔·哈卡森表示。

'Our Series A enabled us to move our lead programs forward and achieve the clinical milestones we set out to reach. This new financing gives us the opportunity to unlock additional value within the broader pipeline by advancing AT-002 and AT-003 towards the clinic, while advancing partnering and out-licensing activities for AT-001 and AT-004,' .

“A轮融资使我们能够推进我们的领先项目，并实现我们设定的临床里程碑。此次新融资为我们提供了机会，通过推动AT-002和AT-003向临床研究阶段迈进，同时推进AT-001和AT-004的合作与对外许可活动，从而在更广泛的产品管线中释放额外价值。”

he added.

他补充道。

AT-002 is a peptide mimetic of the kinase inhibitory region (KIR) domain of suppressor of cytokine signaling 1 (SOCS1), a potent inhibitor of the JAK-STAT signaling pathway. The program is initially being developed for autoimmune uveitis, with potential applications across other autoimmune and inflammatory diseases including lupus, psoriasis, and juvenile dermatomyositis..

AT-002 是细胞因子信号转导抑制因子 1（SOCS1）激酶抑制区（KIR）结构域的肽模拟物，而 SOCS1 是 JAK-STAT 信号通路的有效抑制剂。该药物项目最初针对自身免疫性葡萄膜炎进行开发，并有望应用于其他自身免疫性和炎症性疾病，包括系统性红斑狼疮、银屑病和幼年皮肌炎。

AT-003 is a small-molecule mitophagy and autophagy modulator designed to counteract the consequences of aberrant activity of

AT-003 是一种小分子线粒体自噬和自噬调节剂，旨在对抗异常活性带来的后果

CLEC16A

. Genetic variation involving

. 涉及遗传变异

CLEC16A

has been strongly associated with 16 autoimmune diseases, including lupus, rheumatoid arthritis, multiple sclerosis, and type 1 diabetes, as well as Parkinson's disease. The program is intended to address cellular dysfunction associated with impaired mitochondrial function and autophagy dysregulation..

已与包括狼疮、类风湿性关节炎、多发性硬化症和1型糖尿病在内的16种自身免疫性疾病以及帕金森病密切相关。该计划旨在解决与线粒体功能受损和自噬失调相关的细胞功能障碍。

'AT-002 and AT-003 reflect the same genomics-driven approach on which Arctic Therapeutics was founded, identifying disease biology through human genetics and translating those discoveries into therapeutic interventions,'

“AT-002和AT-003体现了Arctic Therapeutics创立时所秉持的同一基因组驱动方法，即通过人类遗传学识别疾病生物学机制，并将这些发现转化为治疗干预措施。”

ATx founder Dr. Hakon Hakonarson said.

ATx 创始人哈孔·哈科纳森博士表示。

'Both programs target biological pathways implicated across multiple serious diseases both common and rare. Bringing them closer to clinical development significantly expands the potential reach of our pipeline beyond our current clinical-stage programs,'

“这两个项目均针对在多种常见及罕见严重疾病中发挥作用的生物通路。将它们进一步推进至临床开发阶段，将显著扩大我们产品管线的潜在覆盖范围，超越目前处于临床阶段的项目。”

he added.

他补充道。

The company's lead dementia program, AT-001, is an oral investigational treatment designed to prevent and disrupt the aggregation of amyloid, tau and related toxic aggregation proteins. The company has completed the 12-month core treatment period of its pivotal Phase IIb/III study in Hereditary Cystatin C Amyloid Angiopathy (HCCAA), a rare familial form of dementia, with an approved extension continuing to evaluate longer-term treatment..

该公司的领先痴呆症项目AT-001是一种口服在研疗法，旨在预防并阻断淀粉样蛋白、tau蛋白及相关毒性聚集蛋白的聚集。公司已完成其针对遗传性胱抑素C淀粉样血管病（HCCAA，一种罕见的家族性痴呆症）的关键性IIb/III期研究的12个月核心治疗期，并已获准延长研究以继续评估长期治疗效果。

AT-001 is also being evaluated in an ongoing fully recruited randomized, double-blind, placebo-controlled Phase IIa biomarker study in patients with mild cognitive impairment and mild Alzheimer's disease, investigating its effects using blood-based biomarkers and brain imaging. The program is intended to evaluate whether findings from ATx's work in genetically defined amyloid disease can translate into the much larger Alzheimer's disease population..

AT-001 正在一项正在进行、已完成入组的随机、双盲、安慰剂对照的 IIa 期生物标志物研究中接受评估，该研究针对轻度认知障碍和轻度阿尔茨海默病患者，通过血液生物标志物和脑部影像学检查来探究其作用。该项目旨在评估 ATx 在遗传定义的淀粉样蛋白疾病中的研究成果是否能够转化应用于规模大得多的阿尔茨海默病人群。

AT-004, the company's second lead clinical program, is an acetylcholinesterase inhibitor targeting the non-neuronal cholinergic anti-inflammatory pathway, a biological system present in human skin involved in regulating inflammation and pro-inflammatory cytokines such as TNF-α. A Phase IIa signal finding proof-of-concept study in acne vulgaris has been completed, demonstrating favorable safety, tolerability and generating encouraging efficacy signals supporting further clinical development.

AT-004 是该公司第二个主要临床项目，是一种乙酰胆碱酯酶抑制剂，靶向非神经元胆碱能抗炎通路。该通路是存在于人体皮肤中的一种生物系统，参与调节炎症以及肿瘤坏死因子-α（TNF-α）等促炎细胞因子。一项针对寻常痤疮的 IIa 期信号探索性概念验证研究已完成，结果显示其安全性和耐受性良好，并产生了令人鼓舞的疗效信号，支持进一步的临床开发。

The program is initially focused on acne but has potential applications across other inflammatory skin diseases, including atopic dermatitis, rosacea, psoriasis as well as wound healing..

该项目最初专注于痤疮，但在其他炎症性皮肤病（包括特应性皮炎、玫瑰痤疮、银屑病）以及伤口愈合方面也具有潜在应用价值。

Earlier this year, ATx participated in the acquisition of NB-001, a clinical-stage program previously owned by US-based Nobias Therapeutics. The asset, now known as SYN-001, forms the foundation of newly established Synaptiq Therapeutics, which was launched in July 2026 by a consortium including ATx, Sanos Group, an Icelandic investment fund managed by AxUM Securities, and investors in Nobias Therapeutics, including US-based Medical Excellence Capital..

今年早些时候，ATx 参与收购了 NB-001，这是一项此前由美国 Nobias Therapeutics 拥有的临床阶段项目。该资产现名为 SYN-001，构成了新成立的 Synaptiq Therapeutics 的基础。Synaptiq Therapeutics 于 2026 年 7 月由一个财团启动，成员包括 ATx、Sanos Group（由 AxUM Securities 管理的冰岛投资基金）以及 Nobias Therapeutics 的投资者（包括美国的 Medical Excellence Capital）。

SYN-001 is being developed for the treatment of neuropsychiatric symptoms associated with 22q11.2 deletion syndrome (22q11DS). The program has received FDA Rare Pediatric Disease Designation and Orphan Drug Designation and, following positive Phase II clinical results, is being prepared for a Phase IIb clinical trial in North America and Europe.

SYN-001 正在开发中，用于治疗与 22q11.2 缺失综合征（22q11DS）相关的神经精神症状。该项目已获得美国食品药品监督管理局（FDA）的罕见儿科疾病认定和孤儿药认定，并在二期临床试验取得积极结果后，正准备在北美和欧洲开展 IIb 期临床试验。

ATx provides Synaptiq with clinical development infrastructure, scientific expertise, and operational capabilities..

ATx 为 Synaptiq 提供临床开发基础设施、科学专业知识以及运营能力。

Arctic Therapeutics was advised by Arctica Finance as financial advisor and BBA//Fjeldco as legal advisor in connection with the financing.

北极疗法公司（Arctic Therapeutics）在此次融资中聘请了 Arctica Finance 担任财务顾问，聘请了 BBA//Fjeldco 担任法律顾问。

About Arctic Therapeutics

关于 Arctic Therapeutics

Arctic Therapeutics (ATx) is a clinical-stage biopharmaceutical company established in 2015 as a spin-off from the US-based Center for Applied Genomics (CAG), a research center at the Children's Hospital of Philadelphia. The company's diversified pipeline reflects its commitment to addressing diseases with significant unmet medical need by translating human genetic discoveries into safe and effective treatments.

Arctic Therapeutics（ATx）是一家临床阶段的生物制药公司，成立于2015年，是从美国应用基因组学中心（CAG）分拆出来的。CAG是费城儿童医院的一个研究中心。该公司的多元化产品管线反映了其致力于通过将人类遗传学发现转化为安全有效的治疗方法，来满足存在重大未满足医疗需求的疾病治疗领域。

ATx is advancing clinical and preclinical programs across neurology, autoimmune diseases and inflammatory skin conditions and has operations in Iceland and the United States, alongside research and clinical collaborations across Europe. For more information, please visit .

ATx 正在推进神经学、自身免疫性疾病和炎症性皮肤病领域的临床及临床前项目，在冰岛和美国设有运营机构，并在欧洲开展研究与临床合作。欲了解更多信息，请访问。

www.arctictherapeutics.com

and follow Arctic Therapeutics on LinkedIn.

并在 LinkedIn 上关注 Arctic Therapeutics。

About Pekron

关于 Pekron

Pekron is a private investment firm and family office headquartered in Reykjavík, Iceland. The firm invests and manages capital across private and public securities, real estate and other investment opportunities, with a long-term approach to capital allocation. For more information, please visit

Pekron 是一家总部位于冰岛雷克雅未克的私人投资公司和家族办公室。该公司投资于私募和公开证券、房地产及其他投资机会，并管理相关资本，秉持长期资本配置理念。欲了解更多信息，请访问

www.pekron.is

。

About Sanos Group

关于Sanos集团

Sanos Group is a leading specialist provider of clinical study services to the global pharmaceutical and biotechnology industries. Headquartered in Denmark, the group operates across Europe, the United States and Asia and provides clinical development capabilities through specialist CROs, research clinics, technology platforms and clinical supply services.

Sanos Group 是一家领先的临床研究机构（CRO），专注于为全球制药和生物技术行业提供临床研究服务。集团总部位于丹麦，业务遍及欧洲、美国和亚洲，通过专业化的合同研究组织（CRO）、研究中心诊所、技术平台以及临床试验物资供应服务，提供全面的临床开发能力。

Its specialist areas include dermatology, central nervous system disorders and osteoarthritis. For more information, please visit .

其专业领域包括皮肤科、中枢神经系统疾病和骨关节炎。欲了解更多信息，请访问。

www.sanos.com

。

About AxUM Securities and Landvættir

关于 AxUM 证券与 Landvættir

AxUM Securities Ltd.

AxUM 证券有限公司

(AxUM Verðbréf hf.) is an Icelandic licensed alternative investment fund management company headquartered in Akureyri, Iceland. AxUM manages investment funds for professional private investors, including venture capital fund Landvættir. For more information, please visit

AxUM Verðbréf hf. 是一家总部位于冰岛阿克雷里的持牌另类投资基金管理公司。AxUM 为专业私人投资者管理投资基金，包括风险投资基金 Landvættir。欲了解更多信息，请访问

www.axum.is

。

About Kaldbakur:

关于卡尔达巴库尔：

Kaldbakur is an international investment company focused on creating long-term value through active ownership and strategic investments. The company manages a diversified portfolio spanning the seafood industry, tourism, food production, healthcare and a range of smaller businesses, reflecting its commitment to diversification, sustainable growth, and long-term value creation.

Kaldbakur 是一家国际投资公司，专注于通过积极持股和战略投资创造长期价值。该公司管理着一个多元化的投资组合，涵盖海鲜产业、旅游业、食品生产、医疗保健以及众多小型企业，体现了其对多元化、可持续增长和长期价值创造的承诺。

For more information, please visit.

更多信息，请访问。

www.kaldbakur.net

For media inquiries

媒体垂询

Gulli Arnason, Chief Strategy Officer

古利·阿纳森，首席战略官

[email protected]

This information was brought to you by Cision

本信息由 Cision 提供

http://news.cision.com